Effectiveness and cost-effectiveness of prognostic markers in prostate cancer

British Journal of Cancer

Volumn 88, Issue 1, 2003, Pages 31-35

  Calvert, N W ^a   Morgan, A B ^b   Catto, J W F ^c   Hamdy, F C ^c   Akehurst, R L ^b   Mouncey, P ^b   Paisley, S ^b  

^a Fourth Hurdle Consulting Ltd   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Cost effectiveness; DNA ploidy; Prognostic marker; Prostate cancer

Indexed keywords

TUMOR MARKER;

ARTICLE; CANCER GRADING; CONSERVATIVE TREATMENT; COST EFFECTIVENESS ANALYSIS; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE;

COST-BENEFIT ANALYSIS; GENETIC MARKERS; HUMANS; MALE; MODELS, STATISTICAL; PLOIDIES; PROGNOSIS; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY;

EID: 0037434418     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600630     Document Type: Article

References (28)

1. Aus G, Hugosson J (1997) Fifteen-year survival with prostate cancer in Sweden. JAMA 278: 205-206
2. Bostwick DG, Grignon DJ, Hammond ME, Amin MB, Cohen M, Crawford D, Gospadarowicz M, Kaplan RS, Miller DS, Montironi R, Pajak TF, Pollack A, Srigley JR, Yarbro JW (2000) Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124: 995-1000
3. Cantor SB, Spann SJ, Volk RJ, Cardenas MP, Warren MM (1995) Prostate cancer screening: a decision analysis. J Fam Pract 41: 33-41
4. Chamberlain J, Melia J, Moss S, Brown J (1997) The diagnosis, management, treatment and costs of prostate cancer in England and Wales. Health Technol Assess 1(3)
5. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, Chisholm GD, Moskovitz B, Livne PM, Warner J (1994) Results in conservative management of clinically localised prostate cancer. N Engl J Med 330: 242-248
6. Cowen ME, Cahill D, Kattan MW Miles BJ (1996) The value or utility of prostate cancer states. J Urol 155: 376A
7. Dillioglugil O Leibman BD Leibman NS, Kattan MW, Rosas AL, Scardino PT (1997) Risk factors for complications and morbidity after radical retropubic prostatectomy. J Urol 157: 1760-1767
8. Donovan JL, Frankel SJ, Neal DE, Hamdy FC (2001) Screening for prostate cancer in the UK: seems to be creeping in by the back door. BMJ 323: 763-764
9. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE (1993) A decision analysis of alternative treatment strategies for clinically localised prostate cancer. JAMA 269: 2650-2658
10. Han M, Partin AW, Piantadosi S, Epstein J, Walsh PC (2001) ERA specific biochemical recurrence-free survival following radical prostatectomy for clinically localised prostate cancer. J Urol 166: 416-419
11. HM Government Actuarial Department (2001). Interim Life Tables. http://www.gad.gov.uk/b2/b2div10.htm 19-4-2001
12. Johansson JE, Holmberg L, Johansen S, Bergstrom R, Adami HO (1997) Fifteen year survival in prostate cancer. A prospective, population based study in Sweden. JAMA 277: 467-471
13. Kattan MW, Cowen ME, Miles BJ (1997) A decision analysis for treatment of clinically localised prostate cancer. J Gen Intern Med 12: 299-305
14. Kind P, Hardman G, Macran S (1999) UK Population Norms for EQ-5D. No. 172. York, University of York.
15. Litwin MS, Melmed GY, Nakazon T (2001) Life after radical prostatectomy: a longitudinal study. J Urol 166: 587-592
16. Montironi R (2001) Prognostic factors in prostate cancer. BMJ 322: 378-379
17. Netten A, Curtis L (2000) Unit Costs of Health and Social Care. Canterbury: Personal Social Services Research Unit, University of Kent
18. Office for National Statistics (2000) Cancer Statistics: Registrations England and Wales 1994: Series MB1 No. 27. London: Stationary Office
19. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD (1997) Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localised prostate cancer. A multi-institutional update. JAMA 277: 1445-1451
20. Ross JS, Sheehan CE, Ambros RA, Nazeer T, Jennings TA, Kaufman Jr RP, Fisher HA, Rifkin MD, Kallakury BV (1999) Needle biopsy DNA ploidy status predicts grade shifting in prostate cancer. Am J Surg Pathol 23: 296-301
21. Royal Pharmaceutical Society of Great Britain (2001) British National Formulary. http://www.bnf.org 19-6-2001
22. Schroder F, Tribukait B, Bocking A, DeVere White R, Koss L, Lieber M, Stenkvist B, Zetterberg A (1994) Clinical utility of cellular DNA measurements in prostate carcinoma. Consensus Conference on Diagnosis and Prognostic Parameters in Localised Prostate Cancer. Stockholm, Sweden, 12-13 May 1993. Scand J Urol Nephrol 162(Suppl): 51-63
23. Selley S, Donovan J, Faulkner A, Coast J, Gillatt D (1997) Diagnosis, management and screening of early localised prostate cancer. Health Technol Assess 1(2)
24. Steinberg DM, Sauvageot J, Piantadosi S, Epstein JI (1997) Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 21: 566-576.
25. The Fairmount Group (2001) Retail Price Indices History. http://www.fairmount.co.uk/rpi.htm 19-6-2001
26. Veltri RW, Miller MC, Partin AW, Coffey DS, Epstein JI (1996) Ability to predict biochemical progression using Gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei. Urology 48: 685-691
27. Walsh PC, Brooks JA (1997) The Swedish prostate cancer paradox. JAMA 277: 497-498
28. Yoshimura N, Takami N, Ogawa O, Kakehi Y, Okada Y, Fukui T, Yoshida O (1998) Decision analysis for treatment of early stage prostate cancer. Jpn J Cancer Res 89: 681-689